MedPath

A CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF "IRUKAARA PARPAM" IN PATIENT WITH KIDNEY STONE

Phase 2
Completed
Conditions
AZHAL KALLADAIPPU(RENAL CALCULI)
Registration Number
CTRI/2014/08/004931
Lead Sponsor
NATIONAL INSTITUTE OF SIDDHA
Brief Summary

Renal calculusor Nephrolithiasis is one of the most common diseases of the renal system. Itoccurs more frequently in men than in women and in whites than in blacks. It israre in children. Urinary calculusis a stone-like body composed of urinary salts bound together by a colloidmatrix of organic materials. It consists of a nucleus around which concentriclayers of urinary salts are deposited. Nephrolithiasis occursin all parts of the world, with a lower lifetime risk of 2-5 percentages inAsia, 8-15 percentages in the West, and 20 percentages in Saudi Arabia.[9]**.**

In India,the incidence of upper and lower urinary tract calculiis more. With its multifactorial etiology and high rate of recurrence, urinarytract stone disease  becomes a medicalchallenge. The new approach in diagnosis and management like Extra-corporealshock wave lithotripsy (ESWL) and endoscopy surgery are not cost effective tothe lower socio- economic groups, who are mostly affected by urinary calculus,[2]when compared to the treatment with traditional system of medicine, which iscost effective.its give me a motivation to do a study on IRUKAARA PARPAM in thetreatment of azhal kalladaippu.

In the text Siddha vaithiya Patharthagunavilakkam-Thaathu Jeeva Vaguppu ‘**IRUKAARAPARPAMâ€** a Siddha formulation has been specificallyindicated for  kalladaippu. The mode ofpreparation seems to be simple and cost effective.The main  ingrediants of the  above said formulation are vengaram (borax)and padikaaram( alum). Vengaram(Borax) is well known for its karkaraichi(lithotriptic),Siruneerperukki(diuretic) and Azhukalakatri (antiseptic) actions as per Siddhaliterature[15]. Padikaaram (Alum) has Isivakatri(antispasmodic),Azhukalakatri(antiseptic)and Kuruthi pokkadaki(haemostatic) actions as per Siddha literature[16].

The above said drug formulationhas not yet  undergone any safety studiesand yet to be documented clinically. Hence I have selected the siddhaformulation   **“** **IRUKAARA PARPAMâ€** for further clinical evaluation  in **AZHALKALLADAIPPU**.

**IRUKAARA PARPAM**

**METHOD OF PREPARATION:**

INGREDIENTS:

- Purified Vengaram                   - 1palam(35gms)

- Purified Alum                           - 1palam(35gms)

- Lemon juice                               - Required quantity

- **PURIFICATION OF TRIAL DRUGS****:**

- 1**.Vengaram:**

Purification will be done byfrying the Vengaram in a mud vessel until the water content evaporates.

- 2**.Padikaaram:**

Alumwill be mixed  well with water and willbe filtered. The filtrate will be boiled again and allowed to cool.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
40
Inclusion Criteria
  • •Patients who are having the classical symptoms of abdominal pain and distensión, pain from loin to groin, pain in urethra, agonizing pain, dysuria, oliguria, yellow coloured urination, burning micturition, haematuria, nausea and vomiting.
  • •Stone size: ≥4mm and ≤10mm •Patient with renal calculus detected on X-ray KUB or USG abdomen.
  • •History of Recurrence of Renal calculi.
  • •Patient willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 24days but can opt out of the trial of his/her own conscious discretion.
  • •Patients who are willing to take Ultrasonography Investigation (USG- abdomen / KUB) and provide blood and urine samples for laboratory investigation.
Exclusion Criteria

•Stone size 10mm •Pregnancy and lactation •Presence of any associated severe systemic illness, e.g.CA •Patient taking any other lithotriptic agent in the recent past •History of Diabetes/ Hypertension •Renal diseases •Cardiac diseases.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1complete clearance/ reduction in the size of renal calculus in X-ray KUB or USG abdomen.24 DAYS
Secondary Outcome Measures
NameTimeMethod
2.Complete reduction of clinical symptoms and improvement in the lab investigation24DAYS

Trial Locations

Locations (1)

NATIONAL INSTITUTE OF SIDDHA,DEPARTMENT OF MARUTHUVAM,BRANCH I,OPD NO 1

🇮🇳

Kancheepuram, TAMIL NADU, India

NATIONAL INSTITUTE OF SIDDHA,DEPARTMENT OF MARUTHUVAM,BRANCH I,OPD NO 1
🇮🇳Kancheepuram, TAMIL NADU, India
DR B SIVARAJA MANICKAM
Principal investigator
9585695147
sivarajamanickam87@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.